Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial.
暂无分享，去创建一个
R. Paschke | L. Bastholt | M. Schlumberger | M. Brose | B. Jarzab | Yuankai Shi | R. Elisei | S. Siena | D. Mitchell | J. Lettieri | M. Gao | H. Deshpande | C. Peña | C. Fouchardière | C. Kappeler | I. Molnár | Lin Li | H. Walker | K. Prins